Study reference No of patients eligible for analysis TNM stage Therapy and IFN subspecies Dose and schedule—treatment arm Median followup at time of reporting (yrs) Median DFS (mths) Median OS (mths) % Node- positive High dose NCCTG 83-7052 [20 ] 262 II–III (T2-4N0M0/TanyN + M0) IFN-α 2a versus observation IM 20 MU/m^{2} thrice weekly for 4 months 6.1 NS NS 61 ECOG E1684 [21 ] 287 II–III (T4N0M0/TanyN + M0) IFN-α 2b versus observation IV 20 MU/m^{2} 5 days a week for 4 weeks
then
SC 10 MU/m^{2} 3 days a week for 48 weeks 12.6 6.9 S (at 6.9 yrs) NS (at 12 yrs) 89 ECOG E1690 [22 ] 642 II–III (T4N0M0/TanyN + M0) IFN-α 2b—high dose versus low dose versus observation High dose: IV 20 MU/m^{2} 5 days a week for 4 weeks
then
SC 10 MU/m^{2} 3 days a week for 48 weeks Low dose: SC 3MU/m^{2} 2 days a week for 2 years 6.6 4.3 NS 74 ECOG E1694 [23 ] 774 II–III (T4N0M0/TanyN + M0) IFN-α 2b versus GMK vaccine IV 20 MU/m^{2} 5 days a week for 4 weeks
then
SC 10 MU/m^{2} 2 days a week for 48 weeks 2.1 62% (2yr) versus 49% 78% versus 73% 77 ECOG E2696 [25 ] 107 II–III–IV (stage IV: resectable meta static disease) IFN-α 2b with GMK vaccine with and without induction Induction: IV 20 MU/m^{2} 5 days a week for 4 weeks
then
SC 10 MU/m^{2} 3 days a week for 48 weeks No induction: SC 10 MU/m^{2} 3 days a week for 48 weeks 2.4 S S Not available Intermediate dose EORTC 18952 [31 ] 1388 II–III (T4N0M0/TanyN + M0) IFN-α 2b for 1 yr versus 2 yrs versus observation IV 10 MU 5 days a week for 4 weeks
then
SC 10 MU 3 days a week for 1 year OR SC 5 MU 3 days a week for 2 years 1.6 7.2% (NS) 5.4% (NS) 74 EORTC 18991 [91 ] 1256 III (TanyN + M0) PEG IFN-α 2b versus observation SC 6 μ g/kg/week for 8 weeks
then
SC 3 μ g/kg/week for 5 years 3.8 45.6% versus 38.9% (NS) NS 100 Low dose Austrian melanoma cooperative group (AMCG) [92 ] 311 II (T2-4N0M0) IFN-α 2a versus observation SC 3 MU 7 days a week for 3 weeks
then
SC 3 MU 3 days a week for 1 year 3.4 S Not available 0 French melanoma cooperative group (FCGM) [93 ] 499 II (T2-4N0M0) IFN-α 2a versus observation SC 3 MU 3 days a week for 18 months >3 0.74 (HR), S 0.70 (HR), S 0 WHO melanoma program trial 16 [94 ] 444 III (TanyN + M0) IFN-α 2a versus observation SC 3 MU 3 days a week for 36 months 7.3 NS NS 100 Scottish melanoma cooperative group [45 ] 96 II–III (T3-4N0M0/TanyN + M0) IFN-α 2a versus observation SC 3 MU 3 days a week for 6 months >6 NS NS Not available EORTC 18871/DKG 80-1 [42 ] 728 II–III (T3-4N0M0/TanyN + M0) IFN-α 2b versus IFN-γ versus ISCADOR M versus observation IFN-α 2b: SC 1 MU every other day for 12 months IFN-γ : SC 0.2 mg every other day for 12 months 8.2 NS NS 58 UKCCCR/AIM HIGH [44 ] 674 II–III (T3-4N0M0/TanyN + M0) IFN-α 2a versus observation SC 3 MU 3 days a week for 24 months 3.1 NS NS Not available DeCOG [95 ] 840 III (T3anyN + M0) IFN-α 2a SC 3 MU 3 days a week for 18 months (A) versus 5 yrs (B) 4.3 81.9% versus 79.7% NS 85.9% versus 84.9% NS Not available DeCOG [34 ] 444 III (TanyN + M0) IFN-α 2a SC 3 MU 3 days a week for 24 months (A) versus SC 3 MU 3 days a week for 24 months + DTIC 850 mg/m^{2} every 4–8 weeks for 24 months (B) vesus observation (C) 3.9 HR: 0.69 (A) versus 1.01 (B) versus 1.0 (C) HR: 0.62 (A) versus 0.96 (HR) (B) versus 1.0 (C) 100%